

# KOBO BIOTECH LIMITED

(Formerly known as Avon Lifesciences Limited)

E-mail: info@kobobiotech.com • Website : www.avonlifesciences.com

(CIN : L24110TG1993PLC016112)

Asst. General Manager,  
Dept. of Corporate Services.  
Bombay Stock Exchange Limited,  
14th Floor, P.J.Towers, Dalal Street, Fort,  
Mumbai: 400 001

30th May, 2022

Dear Sir/ Madam,

Scrip Name: Kobo Biotech Limited, Scrip Code: 531541

**Sub: OUTCOME OF THE BOARD MEETING: Audited Financial results for the Quarter and year ended 31<sup>st</sup> March, 2022.**

This is to inform you that the Board of Directors of Kobo Biotech Limited at their meeting held today i.e. on Monday, 30<sup>th</sup> May, 2022 inter alia approved the Audited Financial Results of the Company for the quarter and year ended 31<sup>st</sup> March, 2022 alongwith the report of statutory auditor thereon.

Please find enclosed a copy of the audited Financials along with the report from the Statutory Auditors.

The above-referred meeting was commenced at 3:00 p.m. and concluded at 3:45 p.m.

The above is pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, for your information and record.

Thank you,  
**For Kobo Biotech Limited**  
(formerly known as Avon Lifesciences Limited)

*J. N. Patel.*  
**Jignesh Patel**  
Company Secretary



# KOBO BIOTECH LIMITED

(Formerly known as Avon Lifesciences Limited)

E-mail: info@kobobiotech.com • Website : www.avonlifesciences.com

(CIN : L24110TG1993PLC016112)

---

## DECLARATION

**[Pursuant to Regulation 33 (3)(d) of SEBI (Listing Obligation and Disclosure Requirement) (Amendment) Regulations, 2016]**

I, Ajit Kamath, Director of Kobo Biotech Limited, having its Corporate Office at H Wing, 4<sup>th</sup> Floor, Tex Centre, Chandivali, Andheri(E), Mumbai 400 072, Maharashtra, do hereby declare that M/s. N.G. Jain & Co, Statutory Auditors of the Company have carried out audit of the Financial Statements of the Company for the year ended 31<sup>st</sup> March, 2022 and have issued an Audit Report with unmodified opinion.

Yours sincerely,

**For Kobo Biotech Limited**

(formerly known as Avon Lifesciences Limited)



**Ajit Kamath**  
**Director**



**Mumbai**  
**30<sup>th</sup> May, 2022**



CA. Mukesh Mehta  
B. Com. F.C.A.  
CA. Shantilal Jain  
B. Com. F.C.A.  
CA. Prince Kothari  
B. Com. A.C.A.

**N G JAIN & CO**  
**CHARTERED ACCOUNTANTS**

320, Hammersmith Ind. Premises Co-op. Soc. Ltd., Naryan Pathare Marg, Off Sitladevi Temple Road, Mahim (West),  
Mumbai - 400 016 Tel.: 02265010393 / 9082687144

## INDEPENDENT AUDITOR'S REPORT ON AUDIT OF QUARTERLY AND ANNUAL FINANCIAL RESULTS

### TO THE BOARD OF DIRECTORS OF KOBO BIOTECH LIMITED

#### Opinion

We have audited the accompanying quarterly financial result of **Kobo Biotech Limited** ("the Company"), for the quarter ended 31<sup>st</sup> March 2022 and year to date results for the period from 1<sup>st</sup> April 2021 to 31<sup>st</sup> March 2022 attached herewith, being submitted by the company's management pursuant to the requirement of Regulation 33 of the SEBI(Listing Obligation and Disclosure Requirement) Regulation,2015 read with SEBI Circular No, CIR/CFD/CMD1/44/2019 dated 29<sup>th</sup> March 2019.

These quarterly results and year to date financial results have been prepared on the basis of financial statements, which are the responsibility of company's management .Our responsibility is to express an opinion on these financial results based on our audit of such Financial Statements, which was prepared in accordance with the recognition and measurement principles laid down in India Accounting Standards specified under section 133 Companies Act,2013 read with relevant rules issued under companies (accounts) rules 2014 as amended and other accounting principles generally accepted in India.

In our opinion and to the best of our information and according to the explanations given to us these quarterly results and year to date financial results:

- (i) Are presented in accordance with the requirements of Regulation 33 of the SEBI(Listing Obligations and Disclosure Requirements)Regulation.2015,as modified by Circular No.CIR/CFD/FAC/62/2016 dated July 5,2016; and
- (ii) Give a true and fair view in conformity with the aforesaid accounting standards and other accounting principles generally accepted in India of the net Profit and other financial information of the company for the quarter ended 31<sup>st</sup> March 2022 and year to date results for the period from 1<sup>st</sup> April 2021 to 31<sup>st</sup> March 2022.



## **Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Act (SAs). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the independence requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

## **Management's Responsibility for the Financial Statements**

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance, total comprehensive income, changes in equity and cash flows of the Company in accordance with the Ind AS and other accounting principles generally accepted in India. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are responsible for overseeing the Company's financial reporting process.





## Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.



Materiality is the magnitude of misstatements in the financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in

(i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.



for N G JAIN & CO  
Chartered Accountants  
FRN: 103941W

*Prince Kothari*

Mumbai

Date: 30<sup>th</sup> May 2022

UDIN No: 22155819AJWADY4085

Prince Kothari  
Partner

Mem No: 155819

# KOBO BIOTECH LIMITED

CIN: L24110TG1993PLC016112

Regd. Office : 505, Plot No.193 & 193/1, Chandi Nilayam, Samatha Nagar, Bhagyanagar 3rd Phase, Kukatpally, Hyderabad - 500 085

Corp. Office : H Wing, 4th Floor, Tex Centre, Off Saki Vihar Road, Chandivali, Andheri (East), Mumbai - 400 072

## Statement of Audited Financial Results for the quarter and Year ended 31st March, 2022

(Amount in INR Lakhs)

Sr.No.	PARTICULARS	Quarter Ended			Year Ended	
		31.03.2022	31.12.2021	31.03.2021	31.03.2022	31.03.2021
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
I	Income from operations	0.00	0.00	0.00	0.00	0.00
II	Other Income	0.00	0.00	0.00	1.66	3.59
III	Total Income (I+II)	0.00	0.00	0.00	1.66	3.59
IV	Expenditure					
	(a) Cost of raw material consumed	0.00	0.00	0.00	0.00	0.00
	(b) Purchases of stock-in-trade	0.00	0.00	0.00	0.00	0.00
	(c) Employee benefits expense	5.53	10.98	6.39	71.54	139.27
	(d) Finance Cost	0.01	0.01	0.00	13.47	1084.07
	(e) Depreciation and Amortisation expenses	118.13	104.35	138.94	460.60	563.70
	(f) Other Expenses	917.99	19.50	73.50	978.64	139.68
	Total Expenses	1041.66	134.84	218.83	1524.25	1926.72
V	Profit (Loss) before Exceptional Items and Tax (III-IV)	(1,041.66)	(134.84)	(218.83)	(1,522.59)	(1,923.13)
VI	Exceptional items	0.00	0.00	0.00	0.00	0.00
VII	Profit (Loss) before Tax (V-VI)	(1,041.66)	(134.84)	(218.83)	(1,522.59)	(1,923.13)
VIII	Tax expenses					
	(a) Current Tax	0.00	0.00	0.00	0.00	0.00
	(b) Deferred Tax	0.00	0.00	0.00	0.00	0.00
IX	Net Profit (Loss) after tax (VII-VIII)	(1,041.66)	(134.84)	(218.83)	(1,522.59)	(1,923.13)
X	Other Comprehensive Income					
	(i) Items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00
XI	Total Comprehensive Income for the period (IX+X)	(1,041.66)	(134.84)	(218.83)	(1,522.59)	(1,923.13)
XII	Paid-up equity share capital	2382.5	2382.5	2382.5	2382.5	2382.5
XIII	Other Equity				(14,625.31)	(13,102.72)
XIV	Earnings Per Share (Basic and Diluted) (in Rs)	(4.37)	(0.57)	(0.92)	(6.39)	(8.07)

### Notes:

- The above audited standalone financial results, prepared in accordance with the Indian Accounting Standards (Ind AS), the provisions of the Companies Act, 2013 and guidelines issued by the Securities and Exchange Board of India, have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 30th May, 2022.
- The Company operates only in one Business Segment i.e. manufacturing Active Pharmaceutical Ingredients (API)/ Bulk Drugs.
- The number of investor complaints at the beginning and pending at the end of the Quarter were Nil.
- Figures for the quarter ended 31st March are the balancing figures between the audited figures in respect of full financial year and the published year-to-date figures upto the third quarter of the relevant financial year, which were subjected to limited review
- Figures of the previous periods have been regrouped / rearranged wherever considered necessary.

By order of the Board  
For KOB0 BIOTECH LIMITED



*(Handwritten signature)*

Ajit Kamath  
Director

Mumbai  
30-05-2022

# KOBO BIOTECH LIMITED

CIN: L24110TG1993PLC016112

## BALANCE SHEET AS AT 31st MARCH, 2022

(Amount in INR Lakhs)

Particulars	31.03.2022	31.03.2021
<b>ASSETS</b>		
<b>Non-Current Assets</b>		
(a) Property, Plant and Equipment	4,165.93	5,690.69
(b) Capital Work-in-Progress	0.00	225.07
(c) Investment Property	-	-
(d) Goodwill	-	-
(e) Other Intangible Assets	-	-
(f) Intangible Assets Under Development	-	-
(g) Financial Assets		
(i) Investments	0.00	1,219.30
(ii) Trade Receivables	-	-
(iii) Loans	0.00	0.51
(iv) Others	-	-
(e) Deferred Tax Asset (Net)	-	-
(d) Other Non-Current Assets	-	-
	<b>4,165.93</b>	<b>7,135.57</b>
<b>Current assets</b>		
(a) Inventories	1,804.05	5,327.86
(b) Financial Assets		
(i) Investments	-	-
(ii) Trade Receivables	1,179.62	9,247.16
(iii) Cash and Cash Equivalents	8.34	151.70
(iv) Bank Balances Other than (iii) above	4.29	4.29
(v) Loans	-	1.54
(vi) Others	51.84	77.72
(c) Current Tax Assets (Net)	571.60	571.47
(c) Other Current Assets	132.85	541.49
	<b>3,752.59</b>	<b>15,923.23</b>
<b>TOTAL</b>	<b>7,918.52</b>	<b>23,058.80</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
(a) Equity Share capital	2,382.50	2,382.50
(b) Other Equity	(14,625.31)	(13,102.72)
	<b>(12,242.81)</b>	<b>(10,720.22)</b>
<b>Liabilities</b>		
<b>Non Current Liabilities</b>		
(a) Financial Liabilities		
(i) Borrowings	3,353.40	3,353.40
(ii) Trade Payables	-	-
Micro, Small and Medium Enterprises	-	-
Others	-	-
(ii) Other Financial Liabilities	-	-
(b) Provisions	177.74	210.84
(c) Deferred Tax liabilities (Net)	299.01	299.01
(c) Other Non-Current Liabilities	-	-
	<b>3,830.15</b>	<b>3,863.25</b>
<b>Current Liabilities</b>		
(a) Financial Liabilities		
(i) Borrowings	10,718.11	22,699.65
(ii) Trade Payables	-	-
Micro, Small and Medium Enterprises	1.03	1.03
Others	5,216.20	6,044.07
(iii) Other Financial Liabilities	-	-
(b) Other Current Liabilities	377.83	1,133.66
(c) Provisions	-	-
(d) Current Tax Liabilities (Net)	18.01	37.36
	<b>16,331.18</b>	<b>29,915.77</b>
<b>TOTAL</b>	<b>7,918.52</b>	<b>23,058.80</b>

For KOBO BIOTECH LIMITED



*[Signature]*

Ajit Kamath  
Director

Mumbai  
30-05-2022



**CASH FLOW STATEMENT FOR THE YEAR ENDED 31st March 2022**

**(Amount in INR Lakhs)**

<b>Particulars</b>	<b>For the year ended 31st March, 2022</b>	<b>For the year ended 31st March, 2021</b>
<b>A. Cash Flow from Operating Activities</b>		
Net Profit before tax and extraordinary items	(1,522.59)	(1,923.13)
<b>Adjustments for</b>		
Depreciation	460.60	563.70
Interest	13.43	1,084.07
<b>Operating Profits before Working Capital Changes</b>	<b>(1,048.56)</b>	<b>(275.36)</b>
Increase / (Decrease) in Trade Payables	(827.87)	337.16
(Increase) / Decrease in Inventories	3,523.81	0.00
(Increase) / Decrease in Trade Receivables	8,067.54	81.42
Increase / (Decrease) in Other Current Liabilities	(775.17)	34.95
(Increase) / Decrease in other Financial assets	435.95	72.75
<b>Cash Generated from Operations</b>	<b>9,375.70</b>	<b>250.92</b>
Income Tax		
<b>Net Cash flow from operating Activities (A)</b>	<b>9,375.70</b>	<b>250.92</b>
<b>B. Cash Flow from Investing Activities</b>		
Proceeds from sales/Disposal of investments	1,219.30	0.00
Proceeds from sales/Disposal of fixed assets	1,289.22	0.00
Net proceeds /Disposals from advances	0.51	0.00
<b>Net Cash Used in Investing Activities (B)</b>	<b>2,509.03</b>	<b>0.00</b>
<b>C. Cash Flow from Financing Activities</b>		
Proceeds from Long -term borrowings	0.00	(139.88)
Proceeds from non current liabilities	(33.10)	0.00
Proceeds from short -term borrowings	(11,981.55)	1,116.22
Interest	(13.43)	(1,084.07)
<b>Net Cash inflow from Financing Activities (C)</b>	<b>(12,028.08)</b>	<b>(107.73)</b>
<b>Net Increase/(Decrease) in Cash Flow (A+B+C)</b>	<b>(143.35)</b>	<b>143.20</b>
Opening Balance of Cash and Cash Equivalent	155.98	12.78
<b>Closing Balance of Cash and Cash Equivalent</b>	<b>12.63</b>	<b>155.98</b>

**For KOBO BIOTECH LIMITED**

Mumbai  
30-05-2022



**Ajit Kamath**  
**Director**